Non- Alcoholic Steatohepatitis - Pipeline Review, H2 2012


#135314

115pages

Global Markets Direct

$ 2000

In Stock


NonAlcoholic Steatohepatitis Pipeline Review, H2 2012

Global Markets Directs, 'Non-Alcoholic Steatohepatitis Pipeline Review, H2 2012', provides an overview of the Non-Alcoholic Steatohepatitis therapeutic pipeline. This report provides information on the therapeutic development for Non-Alcoholic Steatohepatitis, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Non-Alcoholic Steatohepatitis. 'Non-Alcoholic Steatohepatitis Pipeline Review, H2 2012' is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • A snapshot of the global therapeutic scenario for Non-Alcoholic Steatohepatitis.
  • A review of the Non-Alcoholic Steatohepatitis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. 
  • Coverage of products based on various stages of development ranging from discovery till registration stages.
  • A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
  • Coverage of the Non-Alcoholic Steatohepatitis pipeline on the basis of route of administration and molecule type.
  • Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
  • Key discontinued pipeline projects.
  • Latest news and deals relating to the products.

Reasons to buy

  • Identify and understand important and diverse types of therapeutics under development for Non-Alcoholic Steatohepatitis.
  • Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage. 
  • Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
  • Devise corrective measures for pipeline projects by understanding Non-Alcoholic Steatohepatitis pipeline depth and focus of Non-Alcoholic Steatohepatitis therapeutics. 
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Keywords

Non-Alcoholic Steatohepatitis Therapeutic Products under Development, Key Players in Non-Alcoholic Steatohepatitis Therapeutics, Non-Alcoholic Steatohepatitis Pipeline Overview, Non-Alcoholic Steatohepatitis Pipeline, Non-Alcoholic Steatohepatitis Pipeline Assessment
Table of Contents

Table of Contents 2

List of Tables 7
List of Figures 8
Introduction 9
Global Markets Direct Report Coverage 9
Non-Alcoholic Steatohepatitis Overview 10
Therapeutics Development 11
An Overview of Pipeline Products for Non-Alcoholic Steatohepatitis 11
Non-Alcoholic Steatohepatitis Therapeutics under Development by Companies 13
Non-Alcoholic Steatohepatitis Therapeutics under Investigation by Universities/Institutes 16
Late Stage Products 18
Comparative Analysis 18
Mid Clinical Stage Products 19
Comparative Analysis 19
Early Clinical Stage Products 20
Comparative Analysis 20
Discovery and Pre-Clinical Stage Products 21
Comparative Analysis 21
Non-Alcoholic Steatohepatitis Therapeutics Products under Development by Companies 22
Non-Alcoholic Steatohepatitis Therapeutics Products under Investigation by Universities/Institutes 24
Companies Involved in Non-Alcoholic Steatohepatitis Therapeutics Development 25
Isis Pharmaceuticals, Inc. 25
Takeda Pharmaceutical Company Limited 26
Mochida Pharmaceutical Co., Ltd. 27
Genfit 28
Immuron Limited 29
Raptor Pharmaceuticals Corp. 30
7TM Pharma A/S 31
Phenex Pharmaceuticals AG 32
Wellstat Therapeutics Corporation 33
Conatus Pharmaceuticals Inc. 34
Intercept Pharmaceuticals, Inc. 35
Obio Pharmaceutical Holdings Limited. 36
NasVax Ltd. 37
Stelic Institute & Co. 38
Galmed International Ltd. 39
Connexios Life Sciences Pvt. Ltd. 40
Non-Alcoholic Steatohepatitis Therapeutics Assessment 41
Assessment by Monotherapy Products 41
Assessment by Combination Products 42
Assessment by Route of Administration 43
Assessment by Molecule Type 45
Drug Profiles 48
MND-21 - Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
TAK-438 - Drug Profile 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
TM38837 - Drug Profile 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
GFT505 - Drug Profile 52
Product Description 52
Mechanism of Action 52
R&D Progress 52
PN2XXX - Drug Profile 54
Product Description 54
Mechanism of Action 54
R&D Progress 54
RP103 - Drug Profile 55
Product Description 55
Mechanism of Action 55
R&D Progress 55
G Family Inhibitor For NASH - Drug Profile 58
Product Description 58
Mechanism of Action 58
R&D Progress 58
Obeticholic acid - Drug Profile 59
Product Description 59
Mechanism of Action 59
R&D Progress 59
Obeticholic acid - Drug Profile 61
Product Description 61
Mechanism of Action 61
R&D Progress 61
Aramchol - Drug Profile 63
Product Description 63
Mechanism of Action 63
R&D Progress 63
AK20 - Drug Profile 65
Product Description 65
Mechanism of Action 65
R&D Progress 65
Cysteamine - Drug Profile 66
Product Description 66
Mechanism of Action 66
R&D Progress 66
Pioglitazone - Drug Profile 67
Product Description 67
Mechanism of Action 67
R&D Progress 67
Emricasan - Drug Profile 68
Product Description 68
Mechanism of Action 68
R&D Progress 68
Polypill - Drug Profile 70
Product Description 70
Mechanism of Action 70
R&D Progress 71
Nortriptyline - Drug Profile 72
Product Description 72
Mechanism of Action 72
R&D Progress 72
Metreleptin - Drug Profile 73
Product Description 73
Mechanism of Action 73
R&D Progress 73
Ezetimibe - Drug Profile 74
Product Description 74
Mechanism of Action 74
R&D Progress 74
Cholic Acid - Drug Profile 75
Product Description 75
Mechanism of Action 75
R&D Progress 75
Pentoxifylline - Drug Profile 76
Product Description 76
Mechanism of Action 76
R&D Progress 76
Losartan - Drug Profile 77
Product Description 77
Mechanism of Action 77
R&D Progress 77
Colesevelam - Drug Profile 78
Product Description 78
Mechanism of Action 78
R&D Progress 78
Opti-EPA - Drug Profile 79
Product Description 79
Mechanism of Action 79
R&D Progress 79
TAK-390MR - Drug Profile 80
Product Description 80
Mechanism of Action 80
R&D Progress 80
TAK-390MR - Drug Profile 81
Product Description 81
Mechanism of Action 81
R&D Progress 81
Anti-aCD3 Mab - Drug Profile 82
Product Description 82
Mechanism of Action 82
R&D Progress 82
GR-MD-02 - Drug Profile 84
Product Description 84
Mechanism of Action 84
R&D Progress 84
Pentoxiphylline + Vitamin E - Drug Profile 85
Product Description 85
Mechanism of Action 85
R&D Progress 85
RP104 - Drug Profile 86
Product Description 86
Mechanism of Action 86
R&D Progress 86
IMM-124E - Drug Profile 87
Product Description 87
Mechanism of Action 87
R&D Progress 87
Px-102 - Drug Profile 88
Product Description 88
Mechanism of Action 88
R&D Progress 88
CNX-FC010 - Drug Profile 89
Product Description 89
Mechanism of Action 89
R&D Progress 89
ISIS-DGAT2 - Drug Profile 90
Product Description 90
Mechanism of Action 90
R&D Progress 90
Sodium Alginate - Drug Profile 91
Product Description 91
Mechanism of Action 91
R&D Progress 91
Tranilast - Drug Profile 92
Product Description 92
Mechanism of Action 92
R&D Progress 92
Non-Alcoholic Steatohepatitis Therapeutics Drug Profile Updates 93
Non-Alcoholic Steatohepatitis Therapeutics Discontinued Products 105
Non-Alcoholic Steatohepatitis Therapeutics - Dormant Products 106
Non-Alcoholic Steatohepatitis Product Development Milestones 108
Featured News & Press Releases 108
Jun 25, 2012: Raptor Pharma Begins Dosing In Phase IIb Trial Of RP103 For Treatment Of Non-Alcoholic Steatohepatitis 108
Jun 20, 2012: Genfit To File Investigational New Drug Application With FDA For GFT505 109
May 10, 2012: Genfit Announces Preclinical Data Of GFT505 Promotes Liver Fibrosis Regression 109
Apr 19, 2012: Genfit To Present Latest Clinical Results For GFT505 In NASH At 47th EASL Congress 109
Apr 04, 2012: GENFIT Receives Scientific Advice From EMA On Efficacy Of GFT505 110
Feb 23, 2012: GENFIT Receives New Patents For GFT505 In Major Countries 110
Feb 08, 2012: GENFIT Announces Conclusive Results Of Regulatory Toxicology Studies With GFT505 111
Feb 03, 2012: GENFIT's GFT505-210-6 Phase II Clinical Study Reaches All Primary And Secondary Efficacy Objectives 111
Jan 10, 2012: FDA Clears Investigational New Drug Application & Phase IIb Trial For Immurons Nash/Fatty Liver Therapeutic 113
Dec 19, 2011: GENFIT To Participate At Two International Conferences In San Francisco 113

Appendix 114
Methodology 114
Coverage 114
Secondary Research 114
Primary Research 114
Expert Panel Validation 114
Contact Us 115
Disclaimer 115

Number of Products Under Development for Non-Alcoholic Steatohepatitis, H2 2012 11
Products under Development for Non-Alcoholic Steatohepatitis Comparative Analysis, H2 2012 12
Number of Products under Development by Companies, H2 2012 14
Number of Products under Development by Companies, H2 2012 (Contd..1) 15
Number of Products under Investigation by Universities/Institutes, H2 2012 17
Comparative Analysis by Late Stage Development, H2 2012 18
Comparative Analysis by Mid Clinical Stage Development, H2 2012 19
Comparative Analysis by Early Clinical Stage Development, H2 2012 20
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H2 2012 21
Products under Development by Companies, H2 2012 22
Products under Development by Companies, H2 2012 (Contd..1) 23
Products under Investigation by Universities/Institutes, H2 2012 24
Isis Pharmaceuticals, Inc., H2 2012 25
Takeda Pharmaceutical Company Limited, H2 2012 26
Mochida Pharmaceutical Co., Ltd., H2 2012 27
Genfit, H2 2012 28
Immuron Limited, H2 2012 29
Raptor Pharmaceuticals Corp., H2 2012 30
7TM Pharma A/S, H2 2012 31
Phenex Pharmaceuticals AG, H2 2012 32
Wellstat Therapeutics Corporation, H2 2012 33
Conatus Pharmaceuticals Inc., H2 2012 34
Intercept Pharmaceuticals, Inc., H2 2012 35
Obio Pharmaceutical Holdings Limited., H2 2012 36
NasVax Ltd., H2 2012 37
Stelic Institute & Co., H2 2012 38
Galmed International Ltd., H2 2012 39
Connexios Life Sciences Pvt. Ltd., H2 2012 40
Assessment by Monotherapy Products, H2 2012 41
Assessment by Combination Products, H2 2012 42
Assessment by Stage and Route of Administration, H2 2012 44
Assessment by Stage and Molecule Type, H2 2012 47
Non-Alcoholic Steatohepatitis Therapeutics Drug Profile Updates 93
Non-Alcoholic Steatohepatitis Therapeutics Discontinued Products 105
Non-Alcoholic Steatohepatitis Therapeutics Dormant Products 106
Non-Alcoholic Steatohepatitis Therapeutics Dormant Products (Contd..1) 107
Number of Products under Development for Non-Alcoholic Steatohepatitis, H2 2012 11
Products under Development for Non-Alcoholic Steatohepatitis - Comparative Analysis, H2 2012 12
Products under Development by Companies, H2 2012 13
Products under Investigation by Universities/Institutes, H2 2012 16
Late Stage Products, H2 2012 18
Mid Clinical Stage Products, H2 2012 19
Early Clinical Stage Products, H2 2012 20
Discovery and Pre-Clinical Stage Products, H2 2012 21
Assessment by Monotherapy Products, H2 2012 41
Assessment by Combination Products, H2 2012 42
Assessment by Route of Administration, H2 2012 43
Assessment by Stage and Route of Administration, H2 2012 44
Assessment by Molecule Type, H2 2012 45
Assessment by Stage and Molecule Type, H2 2012 46